Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostate Cancer Recurrent × tempol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Cancer Recurrent 1 Ototoxicity 1 Mucositis 1 Glioblastoma 1 Dermatitis 1 Anus Neoplasms 1

Interventions

tempol 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 TEMPOL-H 1 Sirolimus 1 Nelfinavir 1 Metformin 1 Hydroxychloroquine 1 Diet, Protein-Restricted 1 Dasatinib 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡